Entre peticiones y quejas: actos de habla en las cartas de Bernardo de Bolea y Pedro Pacheco a Antonio Perrenot de Granvela (1551–1557)
Onomázein · 30.11.2025 · 77-99
DOI: 10.7764/onomazein.ne17.03 ↗Kurz gefasst
Fachartikel in der Zeitschrift Onomázein, online erschienen am 30.11.2025. Verfasst von Leyre Martín Aizpuru. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The collection of forty letters written by Bernardo de Bolea and Pedro Pacheco to Antonio Perrenot de Granvela between 1551 and 1557 offers the opportunity to study two fundamental speech acts in the discursive configuration of private letters in the courtly sphere: requests and complaints. Our study shows that, in these letters, acts of petition and complaint are intertwined with different purposes, taking into account, on the one hand, the profiles of each of these nobles and, on the other, their respective personal interests: obtaining favours, advancing their respective careers at court, mediating in political-military conflicts and resolving legal proceedings. In this study, we present the functions and themes of their petitions and complaints, examine their linguistic formulation, and verify their degree of interrelation in discourse as part of the senders' communicative strategy.
Zitieren
APA
Aizpuru, L. M. (2025). Entre peticiones y quejas: actos de habla en las cartas de Bernardo de Bolea y Pedro Pacheco a Antonio Perrenot de Granvela (1551–1557). Onomázein, 77-99. https://doi.org/10.7764/onomazein.ne17.03
Vancouver
Aizpuru LM. Entre peticiones y quejas: actos de habla en las cartas de Bernardo de Bolea y Pedro Pacheco a Antonio Perrenot de Granvela (1551–1557). Onomázein. 2025:77-99. doi:10.7764/onomazein.ne17.03
BibTeX
@article{Aizpuru2025,
author = {Aizpuru, Leyre Martín},
title = {Entre peticiones y quejas: actos de habla en las cartas de Bernardo de Bolea y Pedro Pacheco a Antonio Perrenot de Granvela (1551–1557)},
journal = {Onomázein},
year = {2025},
pages = {77--99},
doi = {10.7764/onomazein.ne17.03}
}
EUVIMED